The hormone-free hot flush drugs also ease menopausal sleep trouble

Sleep disturbance is one of the most common and burdensome symptoms for perimenopausal and postmenopausal women who have moderate to severe hot flushes and night sweats. Hormone therapy is not an option every woman wants or can take, so attention has turned to neurokinin receptor antagonists, a newer class of non-hormonal drugs that has already demonstrated efficacy against the flushes themselves. What has been less clear is whether these drugs also improve the broken sleep that so often travels with the symptoms. This review set out to characterise that sleep effect properly across all the randomised evidence.

The authors conducted a systematic review and pooled analysis of randomised controlled trials following PRISMA and Cochrane recommendations, searching PubMed, Embase and the Cochrane trials register from inception through May 2026. Eligible trials enrolled perimenopausal or postmenopausal women with moderate to severe vasomotor symptoms and compared a neurokinin receptor antagonist against placebo. The outcome was change in a validated patient-reported sleep disturbance questionnaire, the PROMIS Sleep Disturbance Short Form 8b, measured at 4, 12 and 24 weeks. Seven trials involving 3,184 women were included, risk of bias was assessed, and the robustness of the accumulated evidence was formally tested.

The drugs were associated with significant improvements in sleep disturbance compared with placebo at every time point measured: 4 weeks and 12 weeks, each based on 5 studies and 2,869 participants, and 24 weeks, based on 4 studies and 1,798 participants. Both elinzanetant and fezolinetant showed significant benefits in subgroup analyses, with a greater magnitude of effect for elinzanetant. All included trials were judged to be at low risk of bias. However, the certainty of the evidence was rated low because the studies disagreed with each other substantially for reasons the analysis could not explain, which means the true size of the benefit remains uncertain.

These drugs were developed and approved on the strength of their effect on hot flushes, and their effect on sleep had remained incompletely characterised until now. This pooled analysis extends the picture: the sleep benefit is consistent in direction across trials and durable to at least 24 weeks, and the formal sequential analysis suggested enough data has accumulated to trust the overall signal. What stays open is the magnitude, given how much the trials disagreed, and the head-to-head question of whether elinzanetant genuinely beats fezolinetant, which subgroup comparisons can hint at but not settle.

For women whose sleep is being broken by moderate to severe hot flushes and night sweats, this is a reason to know that a non-hormonal drug class appears to help the nights as well as the flushes. It is not evidence about menopausal insomnia in general: every woman in these trials had significant vasomotor symptoms, and the sleep measure was self-reported rather than recorded in a lab. The size of the benefit is genuinely uncertain, so expectations should stay modest. Whether these drugs suit any individual situation is a conversation for a clinician.